Longevity Biotech, a Philadelphia, PA-based developer of a new class of therapeutics via artificial protein technology, received an up to $350k grant from the Thiel Foundation.
The foundation awarded the funding through Breakout Labs, its new revolving fund designed to promote innovation in science and technology.
Founded in 2010 by President Mr. Scott Shandler, Longevity Biotech focuses on pharmaceutical preparation. Its hybridtides are targeted biologic-like molecules which are highly-resistant to breakdown by natural digestive enzymes and tunable to very stable molecular structures.
These features have demonstrated potent therapeutic activity with the possibility of oral biologic delivery.
FinSMEs
23/04/2012